Login to Your Account

ADLR Skyrockets 143%

Cubist to Buy Adolor in Potential $415M Deal

By Marie Powers

Tuesday, October 25, 2011
Cubist Pharmaceuticals Inc., which focuses on the development of drugs to combat conditions prevalent in the hospital setting, will expand its product pipeline with the acquisition of Adolor Corp. in a deal potentially valued at $415 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription